Comparative Study between combination therapy Empagliflozin–Sitagliptin and Empagliflozin–Alogliptin in addition to Metformin assessing the hypoglycemic effect on patients diagnosed with malignancy and poorly controlled Type 2 diabetes mellitus as comorbidity
Abstract
Background: Type 2 diabetes mellitus (T2DM) in patients with malignancy poses unique therapeutic challenges, necessitating effective and safe combination therapies. This study compared the efficacy and safety of empagliflozin–sitagliptin–metformin versus empagliflozin–alogliptin–metformin in poorly controlled T2DM with coexisting cancer. Methods: Prospective, randomized, open-label clinical trial of 12 weeks was performed in 120 patients with T2DM and controlled malignancy. Two groups were randomized: Group A, who received empagliflozin 10 mg combined with sitagliptin 100 mg along with metformin, and Group B, who received empagliflozin 10 mg combined with alogliptin 25 mg along with metformin. Primary endpoint was HbA1c change; secondary endpoints were fasting plasma glucose (FPG), postprandial glucose (PPG), body weight, lipid profile, and adverse events. Data were examined using repeated-measures ANOVA and independent t-tests with p<0.05 being significant. Results: Baseline demographics were similar between groups. At 12 weeks, Group A had a larger mean decrease in HbA1c (−1.4% ± 0.3) than Group B (−1.1% ± 0.4; p=0.02). FPG and PPG also dropped significantly lower in Group A (−37.7 mg/dL and −54.1 mg/dL, respectively) than Group B (−31.7 mg/dL and −46.2 mg/dL; p<0.05). Both regimens were tolerated without difficulty, with minimal hypoglycemia and urinary tract infection being the only adverse events noted, and no deterioration of malignancy symptoms. Conclusion:…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 120 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.